ChromaDex (NASDAQ:CDXC) Cut to “Buy” at StockNews.com

StockNews.com downgraded shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday.

Several other analysts have also recently commented on the stock. Roth Mkm increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright increased their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

ChromaDex Stock Performance

Shares of CDXC opened at $5.41 on Tuesday. The company has a market cap of $413.23 million, a price-to-earnings ratio of 541.54 and a beta of 2.16. The stock has a fifty day moving average price of $5.85 and a two-hundred day moving average price of $4.06. ChromaDex has a 52-week low of $1.36 and a 52-week high of $7.97.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same period in the previous year, the business posted ($0.01) earnings per share. As a group, research analysts predict that ChromaDex will post 0.04 EPS for the current fiscal year.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. acquired a new position in ChromaDex in the third quarter valued at about $68,000. Barclays PLC increased its stake in shares of ChromaDex by 322.1% in the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after acquiring an additional 53,472 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ChromaDex by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after acquiring an additional 17,963 shares during the period. Jane Street Group LLC boosted its stake in ChromaDex by 100.3% during the 3rd quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock worth $167,000 after acquiring an additional 22,889 shares during the last quarter. Finally, State Street Corp grew its holdings in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the period. 15.41% of the stock is owned by institutional investors and hedge funds.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.